SEC	Form	4
-----	------	---

L

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Ľ	Check this box if no longer subject to
	Section 16. Form 4 or Form 5 obligations
l	may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						
1. Name and Address of Reporting Person * Jagpal Sukhi		2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>SUTRO BIOPHARMA, INC.</u> [STRO ]		tionship of Reporting Persor all applicable)	(s) to Issuer 10% Owner	
	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/06/2025		Director Officer (give title below)	Other (specify below)	
C/O SUTRO BIOPHARMA, INC. 111 OYSTER POINT BOULEVARD		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi X	, , ,		
(Street) SOUTH SAN FRANCISCO	94080			Form filed by More than (	One Reporting Person	
	(Zip)	retive Securities Accurred Dispessed of an Deposition				

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

I. Title of Security (Instr. 3)	Date (Month/Day/Year)	 Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	(Instr. 4)	Beneficial Ownership
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative E		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			Securities Beneficially Owned	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to buy)	\$0.85	06/06/2025		A		50,000		(1)	06/06/2035	Common Stock	50,000	\$ <b>0</b>	50,000	D	

#### Explanation of Responses:

1. The option vests as to 8.33% of the total shares monthly, commencing July 6, 2025, with 100% of the total shares vested and exercisable on the earlier of the date of the issuer's 2026 annual stockholders meeting or June 6, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.

> /s/ David Pauling as attorney-in-06/10/2025 fact

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.